CytoDyn
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of CytoDyn generated cash of -$10,982,000, which is more than the previous year. Cash used in financing activities reached the amount of $11,748,000 last year. Net change in cash is therefore $766,000.
Cash Flow
| 2015 | -12.01M | -18.58K | 8.19M |
|---|---|---|---|
| 2016 | -24.81M | -11.94K | 33.41M |
| 2017 | -26.73M | -11.11K | 18.87M |
| 2018 | -29.89M | 0 | 29.35M |
| 2019 | -50.46M | -45.28K | 52.74M |
| 2020 | -68.80M | -41.09K | 79.67M |
| 2021 | -117.57M | -122K | 137.34M |
| 2022 | -77.72M | 0 | 48.01M |
| 2023 | -25.11M | 0 | 29.92M |
| 2024 | -10.98M | 0 | 11.74M |
CYDY Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 9.04M | 4.23M | 33.94M | 14.29M | 3.46M | 1.23M | 1.77M | 9.64M | 1.05M | 4.88M |
Operating activities | ||||||||||
Net income | -49.84M | -79.82M | -210.82M | -154.67M | -124.40M | -56.18M | -50.14M | -25.76M | -25.70M | -25.08M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 29K | 175K | 781K | 1.79M | 2.03M | 1.24M | 356.12K | 366.38K | 361.61K | 360.58K |
Stock-based compensation expense | 2.41M | 4.27M | 6.26M | 10.42M | 6.54M | 3.38M | 0 | 1.20M | 2.35M | 631.30K |
| Deferred income tax benefit | 2.41M | 4.27M | 6.26M | 10.42M | 6.54M | 3.38M | 0 | 1.20M | 2.35M | 631.30K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | -53.01M | -19.03M | -90.82K | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 2.06M | -74.33M | -19.14M | 90.82K | 0 | 0 | 0 | 0 |
Accounts payable | 10.76M | -3.09M | -2.71M | 53.01M | 19.03M | 1.74M | 12.36M | 1.50M | 0 | 7.44M |
Cash generated by operating activities | -10.98M | -25.11M | -77.72M | -117.57M | -68.80M | -50.46M | -29.89M | -26.73M | -24.81M | -12.01M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | -122K | -41.09K | -45.28K | 0 | -11.11K | -11.94K | -18.58K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | -122K | -41.09K | -45.28K | 0 | -11.11K | -11.94K | -18.58K |
Financing activities | ||||||||||
Common Stock Issued | 9.13M | 25.78M | 41.19M | 1M | 12.66M | 38.26M | 25.22M | 19.13M | 37.56M | 0 |
Payments for dividends | 0 | 0 | 0 | -243K | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 138.32M | -8.34K | 0 | -102 | 0 | 0 | 0 |
Repayments of term debt | 2.01M | 895K | 0 | -950K | -2.18M | 14.87M | -259.15K | 1.15M | -789.14K | 7.48M |
Cash used in financing activities | 11.74M | 29.92M | 48.01M | 137.34M | 79.67M | 52.74M | 29.35M | 18.87M | 33.41M | 8.19M |
Net Change In Cash | 766K | 4.81M | -29.71M | 19.65M | 10.82M | 2.23M | -544.13K | -7.86M | 8.59M | -3.83M |
Cash at end of period | 9.81M | 9.04M | 4.23M | 33.94M | 14.29M | 3.46M | 1.23M | 1.77M | 9.64M | 1.05M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |